Close

Adverum Biotechnologies (ADVM) Provides Update on ADVM-022 and INFINITY Trial in Patients with DME, No Longer Plans Future Development for DME

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. SHW
3. SPY
4. AMZN
5. TSLA
6. SPOT
7. NVDA
8. CDNS
9. ADBE
10. MTTR


Go back to Adverum Biotechnologies (ADVM) Provides Update on ADVM-022 and INFINITY Trial in Patients with DME, No Longer Plans Future Development for DME
(NASDAQ: ADVM) Delayed: 11.23 -0.11 (0.97%)
Previous Close $11.34    52 Week High $4.86 
Open $11.31    52 Week Low $2.74 
Day High $11.31    P/E N/A 
Day Low $11.23    EPS $0.00 
Volume 1,354